SEC Form 4 · accession 0001144204-18-063628
Synthetic Biologics, Inc. · SYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven A Shallcross
Officer — CEO and CFO · Director
Period of report
Dec 6, 2018
Accepted (ET)
Dec 7, 2018 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000894158
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.6895 | Dec 6, 2018 | A | 200,000 | A | Dec 6, 2018 | Dec 6, 2025 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1These options will vest monthly on a pro rata basis over 36 consecutive months.